1) AbbVie, Bristol-Myers get FDA nod for hep C treatments – Reuters, 7/24/2015
The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections. The regulator cleared AbbVie Inc’s Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co’s Daklinza, used to treat HCV genotype 3 infections.
2) Regeneron, Sanofi Launch $2B+ Immuno-Oncology Collaboration – GENNews, 7/28/2015
Regeneron Pharmaceuticals and Sanofi said today they have launched a new global collaboration to discover, develop, and commercialize new immuno-oncology antibody treatments, in a deal that could generate more than $2 billion for Regeneron.
3) Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid – Reuters, 7/27/2015
Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva’s position as the world’s No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential “transformational” acquisitions.
4) Amgen wins new myeloma nod for blockbuster hopeful Kyprolis – FiercePharma, 7/27/2015
Amgen ($AMGN), which has been looking to steal market share from Celgene’s ($CELG) Pomalyst in treating multiple myeloma, has won a new FDA approval for Kyprolis that will help it in that fight.
5) MassBio’s startup mentoring program takes on Baxalta as co-sponsor – FiercePharma, 7/27/2015
After six years, the organizers of a free mentoring service for health care startups say theirs has grown to be one of the leading programs to help covert academic discoveries into actual companies in the area, with about 150 mentors available to provide business advice.
MassCONNECT, the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences industry, kicked off its second cycle of 2015 with a Technology Showcase at LabCentral on Tuesday, July 28th. At the Showcase, the chosen entrepreneurs presented their ideas to a room of industry executives and potential mentors for early feedback.
First up to present was Jernej Godec, co-founder of MIFCOR with Nicole Bucala. MIFCOR is developing a first-in-class biologic therapeutic that targets a novel biological pathway to protect tissue from cell death associated with heart attacks, acute kidney injury, and other indications.
Next up was Griffin Weber, co-founder of Pretium with Isaac Kohane. Pretium is developing a medical informatics-based platform to better match patients with clinical trials, accelerate recruitment, cut overall trial costs and ultimately reduce healthcare costs.
Dimitar Alargov took to the podium next. Alargov founded ACANS Pharmaceuticals with Gerhard Wagner. ACANS Pharmaceuticals is a biopharmaceutical startup involved in the discovery, development and commercialization of a new class of oncology drugs focused on a new universal target for the suppression of tumor growth.
John Lewandowski, founder of Disease Diagnostic Group, wrapped up the showcase. Disease Diagnostic Group is using magnets and light to detect malaria and other infectious diseases in less than 60 seconds at 1/10th the cost and 100x the detection limit of current solutions.
Read the press release announcing the companies and check out article in the BBJ on this MassCONNECT cycle’s entrepreneurs!‘s
MassCONNECT also launched its new Twitter handle at the event. Be sure to follow @Mass_CONNECT for the latest from and for entrepreneurs in the life sciences!
1) Pfizer claims more R&D space in Cambridge, MA, settling into a biotech hotbed – FierceBiotech, 7/22/2015
Pfizer ($PFE), among the horde of drugmakers looking to Cambridge, MA, for innovation, is expanding its outpost in the city’s Kendall Square neighborhood, planning to plant about 1,000 workers in what has become biotech’s fastest-growing neighborhood.
2) First case of prolonged remission in HIV-infected child reported – PharmaLive, 7/21/2015
Doctors have found that an 18-year-old woman infected with HIV at birth via mother-to-child transmission has been in remission despite not receiving any antiretroviral therapy for the past 12 years. Researchers from the HIV, Inflammation and Persistence Unit at the Institut Pasteur in Paris believe that the patient has benefited from treatment initiated shortly after birth and ended 6 years later.
3) With flexible systems, GE aims to disrupt biotech drug making – Boston Globe, 7/19/2015
General Electric Co. isn’t anybody’s idea of a scrappy upstart. But the giant company hopes its life sciences division, one of its fastest-growing niche businesses, will play the role of industry disruptor as the manufacturing of biotech drugs shifts from big-batch production toward more flexible systems.
4) Alzheimer’s drugs show some promise in recent studies – Boston Globe, 7/22/2015
Clinical data released Wednesday contained encouraging findings — but also reasons for caution — on a pair of experimental drugs to treat Alzheimer’s disease, an affliction robbing tens of millions of people worldwide of their memory and cognition.
5) Merck, Baupost join $55M investment in early-stage biotech, RaNA – BBJ, 7/24/2015
After selling his company Idenix Pharmaceuticals to Merck & Co. for $3.9 billion last August, Ronald Renaud has received support again from the New Jersey drug giant, this time in financing for his new company.
This month, Peter Abair officially began his role as Executive Director of the MassBioEd Foundation, MassBio’s sister organization with a mission to engage science teachers, inspire students to pursue STEM, and guide tomorrow’s life sciences workforce. We sat down with Pete to talk about his vision for the future of MassBioEd.
Q: Why did you decide to apply for the Executive Director position at MassBioEd?
A: I served as director of economic development for nine years at MassBio. This brought me into contact often with MassBioEd and led to several significant collaborations on education and training issues. When Lance Hartford informed me that he was moving on, I immediately pursued the position. MassBioEd has always been in the vanguard of the STEM education movement. Knowing firsthand how important life sciences education and workforce development is to companies considering location to or expansion in Massachusetts, I recognized the critical role that MassBioEd plays and wanted to be part of it.
Q: How do you think your former role at MassBio (as well as your many years spent in government) will help shape your impact at MassBioEd?
A: I’ve found, both at MassBio and in my past government experience, that you become a valued partner when you are able to master information and present it in a helpful manner to stakeholders. One way to advance the position of Massachusetts as a premier global center for biopharmaceutical research and commercialization, is by demystifying the pathway from the classroom to the workplace. We will be able to do that because we’ll master the information needed to be an effective, trusted guide for educators, students, and industry in growing a workforce that seeks to meet unmet medical needs globally.
Q: What is your vision for MassBioEd?
A: At its core, MassBioEd is about engaging teachers, inspiring students and guiding the workforce of tomorrow in this incredible life sciences industry. In BioTeach, we have the best-in-class program that provides critical, lab-based training to public high schools teachers, who, in turn, inspire students across the state to pursue studies in science. Through the establishment of our upcoming job trends and forecasting program, we will be able to effectively guide educators and trainers in the development of curricula that enables graduates to have the skills needed to work in the life sciences. Industry will benefit greatly by having a trusted source for information about workforce.
Q: Where do you see the organization in 10 years?
A: Fundamentally, our focus is and will be in science classrooms throughout Massachusetts. The value of exposing students to lessons in biotechnology is self-evident. As they are now, our lab-based educational programs will be providing teachers and students with instruction that is current with the biotechnology field. We will also be the essential resource – to educators and industry alike – for information on job-trends and skills requirements for careers in the industry.
Support MassBioEd and Pete in his new role at MassBio’s 21st Annual Golf Classic to benefit MassBioEd on September 11th at the Pinehills Golf Club in Plymouth, MA! All proceeds support the MassBioEd and their mission to inspire students to pursue STEM.
On Thursday July 16th, people from all across the life sciences sector came together to learn about the future of the industry in the Cambridge vector. Read on to hear the top 3 takeaways from the Forum.
1) The History of Kendall Square
Peter Abair, Executive Director of MassBioEd, kicked off the event with a history of Kendall Square, noting how quickly it’s grown to become the world’s number one hub for life sciences.
A slide from his presentation depicts the movement of big pharma to East Cambridge over the past 15+ years.
2) Kendall Square has it all
It comes as no surprise that Kendall Square is king.
Quotes from the panelists support this notion:
Big companies are equally interested alliances as they are in novel therapeutics which is why they pick Kendall Square.” – Peter Abair
This is a place to have a career, it’s not a place to have a job.”- Steven Gullans, PhD, Managing Director at Excel Medical Ventures, and author of Evolving Ourselves
One of our biggest assets is the talent pool we have here in Massachusetts.” – Brad Rosenblum, Chief Financial & Administrative Officer at the Massachusetts Life Sciences Center (MLSC)
Also mentioned was the “incredible ecosystem” and “palpable energy” that exists in Kendall Square. It allows for a wealth of networking opportunity and supports innovation.
3) There’s life outside of Kendall Square
A major focus of the Forum was that there are a number of life sciences companies outside of Kendall Square that have begun to create their own “microclusters” – and they are thriving! The panelists as well as the interactive audience suggested that there is plenty of opportunity for companies to grow outside of Kendall Square. With limited space and rising costs, Kendall Square is no longer an option for many companies but the surrounding communities are. Another slide from the Forum depicts the clusters that exist around Massachusetts and the abundance of opportunity across the State.